Genocea Biosciences (GNCAQ) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GNCAQ vs. NAVB, SCPS, VAXX, EVLO, CMRA, GNCA, ARDS, STAB, AMPE, and CLVRShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and Clever Leaves (CLVR). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Clever Leaves Genocea Biosciences (NASDAQ:GNCAQ) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Does the media refer more to GNCAQ or NAVB? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Navidea Biopharmaceuticals Neutral Do institutionals and insiders hold more shares of GNCAQ or NAVB? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is GNCAQ or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has more risk & volatility, GNCAQ or NAVB? Genocea Biosciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Which has better earnings & valuation, GNCAQ or NAVB? Genocea Biosciences has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea BiosciencesN/AN/AN/AN/AN/ANavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/A SummaryNavidea Biopharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCAQ vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$204.23M$5.54B$8.95BDividend YieldN/AN/A5.38%4.08%P/E RatioN/AN/A27.4020.04Price / SalesN/A221.46419.65118.51Price / CashN/A22.4436.6357.47Price / BookN/A5.618.085.67Net IncomeN/A-$96.61M$3.16B$248.47M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-80.0%$20K$8.13K0.0010SCPSScopus BioPharmaN/A$0.00-97.0%N/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00-66.7%N/A-90.3%$13KN/A0.0090Gap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Upcoming EarningsCMRAComera Life SciencesN/A$0.00flatN/A-99.2%$6K$1.00M0.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio Pharmaceuticals0.0645 of 5 stars$0.00flatN/AN/A$3KN/A0.0020Gap DownCLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Clever Leaves Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCAQ) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
